

## HR 878

Right to Try Act of 2017

**Congress:** 115 (2017–2019, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Feb 6, 2017

**Current Status:** Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.

**Latest Action:** Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations. (Mar 2, 2017)

**Official Text:** <https://www.congress.gov/bill/115th-congress/house-bill/878>

### Sponsor

---

**Name:** Rep. Biggs, Andy [R-AZ-5]

**Party:** Republican • **State:** AZ • **Chamber:** House

## Cosponsors (89 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Banks, Jim [R-IN-3]	R · IN		Feb 6, 2017
Rep. Barr, Andy [R-KY-6]	R · KY		Feb 6, 2017
Rep. Brat, Dave [R-VA-7]	R · VA		Feb 6, 2017
Rep. Bridenstine, Jim [R-OK-1]	R · OK		Feb 6, 2017
Rep. Carson, Andre [D-IN-7]	D · IN		Feb 6, 2017
Rep. Cramer, Kevin [R-ND-At Large]	R · ND		Feb 6, 2017
Rep. Duncan, Jeff [R-SC-3]	R · SC		Feb 6, 2017
Rep. Fitzpatrick, Brian K. [R-PA-8]	R · PA		Feb 6, 2017
Rep. Franks, Trent [R-AZ-8]	R · AZ		Feb 6, 2017
Rep. Gohmert, Louie [R-TX-1]	R · TX		Feb 6, 2017
Rep. Grothman, Glenn [R-WI-6]	R · WI		Feb 6, 2017
Rep. Issa, Darrell E. [R-CA-49]	R · CA		Feb 6, 2017
Rep. Lamborn, Doug [R-CO-5]	R · CO		Feb 6, 2017
Rep. Lance, Leonard [R-NJ-7]	R · NJ		Feb 6, 2017
Rep. Lewis, Jason [R-MN-2]	R · MN		Feb 6, 2017
Rep. Marino, Tom [R-PA-10]	R · PA		Feb 6, 2017
Rep. McSally, Martha [R-AZ-2]	R · AZ		Feb 6, 2017
Rep. Messer, Luke [R-IN-6]	R · IN		Feb 6, 2017
Rep. Olson, Pete [R-TX-22]	R · TX		Feb 6, 2017
Rep. Pittenger, Robert [R-NC-9]	R · NC		Feb 6, 2017
Rep. Rohrabacher, Dana [R-CA-48]	R · CA		Feb 6, 2017
Rep. Rokita, Todd [R-IN-4]	R · IN		Feb 6, 2017
Rep. Schweikert, David [R-AZ-6]	R · AZ		Feb 6, 2017
Rep. Sensenbrenner, F. James, Jr. [R-WI-5]	R · WI		Feb 6, 2017
Rep. Smucker, Lloyd [R-PA-16]	R · PA		Feb 6, 2017
Rep. Stewart, Chris [R-UT-2]	R · UT		Feb 6, 2017
Rep. Yoho, Ted S. [R-FL-3]	R · FL		Feb 6, 2017
Rep. Bacon, Don [R-NE-2]	R · NE		Feb 14, 2017
Rep. Gaetz, Matt [R-FL-1]	R · FL		Feb 14, 2017
Rep. Griffith, H. Morgan [R-VA-9]	R · VA		Feb 14, 2017
Rep. Hensarling, Jeb [R-TX-5]	R · TX		Feb 14, 2017
Rep. Abraham, Ralph Lee [R-LA-5]	R · LA		Feb 16, 2017
Rep. Posey, Bill [R-FL-8]	R · FL		Feb 16, 2017
Rep. Sinema, Kyrsten [D-AZ-9]	D · AZ		Feb 16, 2017
Rep. Graves, Tom [R-GA-14]	R · GA		Feb 21, 2017
Rep. Tipton, Scott R. [R-CO-3]	R · CO		Feb 21, 2017
Rep. Arrington, Jodey C. [R-TX-19]	R · TX		Mar 7, 2017
Rep. Correa, J. Luis [D-CA-46]	D · CA		Mar 13, 2017
Rep. Faso, John J. [R-NY-19]	R · NY		May 16, 2017
Rep. Polis, Jared [D-CO-2]	D · CO		Jun 6, 2017
Rep. Poe, Ted [R-TX-2]	R · TX		Jun 13, 2017

Cosponsor	Party / State	Role	Date Joined
Rep. Hartzler, Vicky [R-MO-4]	R · MO		Jul 12, 2017
Rep. Comstock, Barbara [R-VA-10]	R · VA		Aug 8, 2017
Rep. Gosar, Paul A. [R-AZ-4]	R · AZ		Oct 12, 2017
Rep. Meadows, Mark [R-NC-11]	R · NC		Oct 31, 2017
Rep. Brooks, Mo [R-AL-5]	R · AL		Nov 29, 2017
Rep. Allen, Rick W. [R-GA-12]	R · GA		Jan 12, 2018
Rep. Chabot, Steve [R-OH-1]	R · OH		Jan 12, 2018
Rep. Harris, Andy [R-MD-1]	R · MD		Jan 12, 2018
Rep. LaMalfa, Doug [R-CA-1]	R · CA		Jan 12, 2018
Rep. Norman, Ralph [R-SC-5]	R · SC		Jan 12, 2018
Rep. Rothfus, Keith J. [R-PA-12]	R · PA		Jan 12, 2018
Rep. Yoder, Kevin [R-KS-3]	R · KS		Jan 12, 2018
Rep. Marshall, Roger [R-KS-1]	R · KS		Jan 16, 2018
Rep. Roe, David P. [R-TN-1]	R · TN		Jan 16, 2018
Rep. Barletta, Lou [R-PA-11]	R · PA		Feb 2, 2018
Rep. Budd, Ted [R-NC-13]	R · NC		Feb 2, 2018
Rep. Garrett, Thomas A., Jr. [R-VA-5]	R · VA		Feb 2, 2018
Rep. Hice, Jody B. [R-GA-10]	R · GA		Feb 2, 2018
Rep. Hill, J. French [R-AR-2]	R · AR		Feb 2, 2018
Rep. Labrador, Raul R. [R-ID-1]	R · ID		Feb 2, 2018
Rep. Tenney, Claudia [R-NY-22]	R · NY		Feb 2, 2018
Rep. Thompson, Glenn [R-PA-5]	R · PA		Feb 2, 2018
Rep. Walberg, Tim [R-MI-7]	R · MI		Feb 2, 2018
Rep. King, Peter T. [R-NY-2]	R · NY		Feb 5, 2018
Rep. DesJarlais, Scott [R-TN-4]	R · TN		Feb 6, 2018
Rep. Gallagher, Mike [R-WI-8]	R · WI		Feb 6, 2018
Rep. Gibbs, Bob [R-OH-7]	R · OH		Feb 6, 2018
Rep. Higgins, Clay [R-LA-3]	R · LA		Feb 6, 2018
Rep. Mooney, Alexander X. [R-WV-2]	R · WV		Feb 6, 2018
Rep. Weber, Randy K., Sr. [R-TX-14]	R · TX		Feb 6, 2018
Rep. Blum, Rod [R-IA-1]	R · IA		Feb 7, 2018
Rep. Johnson, Mike [R-LA-4]	R · LA		Feb 7, 2018
Rep. Jordan, Jim [R-OH-4]	R · OH		Feb 7, 2018
Rep. Perry, Scott [R-PA-4]	R · PA		Feb 7, 2018
Rep. Ratcliffe, John [R-TX-4]	R · TX		Feb 7, 2018
Rep. Sanford, Mark [R-SC-1]	R · SC		Feb 7, 2018
Rep. Luetkemeyer, Blaine [R-MO-3]	R · MO		Feb 8, 2018
Rep. Buck, Ken [R-CO-4]	R · CO		Feb 14, 2018
Rep. Byrne, Bradley [R-AL-1]	R · AL		Feb 15, 2018
Rep. Bost, Mike [R-IL-12]	R · IL		Feb 16, 2018
Rep. Handel, Karen C. [R-GA-6]	R · GA		Feb 16, 2018
Rep. Coffman, Mike [R-CO-6]	R · CO		Feb 20, 2018

Cosponsor	Party / State	Role	Date Joined
Rep. Buchanan, Vern [R-FL-16]	R · FL		Feb 23, 2018
Rep. Comer, James [R-KY-1]	R · KY		Feb 23, 2018
Rep. Pearce, Stevan [R-NM-2]	R · NM		Feb 27, 2018
Rep. Black, Diane [R-TN-6]	R · TN		Mar 5, 2018
Rep. Herrera Beutler, Jaime [R-WA-3]	R · WA		Mar 5, 2018
Rep. Culberson, John Abney [R-TX-7]	R · TX		May 21, 2018

## Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Feb 10, 2017
Judiciary Committee	House	Referred to	Mar 2, 2017
Judiciary Committee	House	Referred to	Mar 2, 2017

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

Bill	Relationship	Last Action
115 S 204	Related bill	May 30, 2018: Became Public Law No: 115-176.
115 HR 2368	Related bill	Jun 7, 2017: Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.

## Summary (as of Feb 6, 2017)

### Right to Try Act of 2017

This bill requires the federal government to allow unrestricted manufacturing, distribution, prescribing, and dispensing of experimental drugs, biological products, and medical devices that are: (1) intended to treat a patient who has been diagnosed with a terminal illness, and (2) authorized by state law. The federal government must allow unrestricted possession and use of such treatments by patients certified by a physician as having exhausted all other treatment options.

A manufacturer, distributor, prescriber, dispenser, possessor, or user of such a treatment has no liability regarding the treatment.

The outcome of manufacture, distribution, prescribing, dispensing, possession, or use of such a treatment may not be used by a federal agency to adversely impact review or approval of the treatment.

The treatment must: (1) have successfully completed a phase 1 (initial, small scale) clinical trial; (2) remain under investigation in a clinical trial approved by the Food and Drug Administration; and (3) not be approved, licensed, or cleared for sale under the Federal Food, Drug, or Cosmetic Act or the Public Health Service Act.

## Actions Timeline

---

- **Mar 2, 2017:** Referred to the Subcommittee on the Constitution and Civil Justice.
- **Mar 2, 2017:** Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
- **Feb 10, 2017:** Referred to the Subcommittee on Health.
- **Feb 6, 2017:** Introduced in House
- **Feb 6, 2017:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.